Two Sigma Securities LLC Purchases Shares of 12,525 Halozyme Therapeutics, Inc. $HALO

Key Points

• Institutional ownership increased: Two Sigma Securities acquired 12,525 Halozyme shares worth approximately $980,000, while several other investors also added positions. Institutions collectively own 97.79% of the company.
• Strong quarterly performance: Halozyme reported quarterly EPS of $2.28, exceeding estimates of $1.79, and revenue of $481 million, up 47.7% year over year and above the $402.28 million consensus.
• Analyst sentiment remains positive despite insider selling: Directors sold shares under pre-arranged 10b5-1 plans, while analysts maintained a “Moderate Buy” consensus, with nine Buy ratings and an average target price of $91.20.

Two Sigma Securities LLC purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 12,525 shares of the biopharmaceutical company's stock, valued at approximately $980,000.

Other large investors also recently made changes to their positions in the company. Cookson Peirce & Co. Inc. acquired a new position in Halozyme Therapeutics in the 2nd quarter worth $486,000. Royal London Asset Management Ltd. boosted its position in shares of Halozyme Therapeutics by 12.4% during the second quarter. Royal London Asset Management Ltd. now owns 1,810,815 shares of the biopharmaceutical company's stock worth $141,732,000 after buying an additional 200,262 shares during the period. Hsbc Holdings PLC boosted its position in shares of Halozyme Therapeutics by 452.1% during the second quarter. Hsbc Holdings PLC now owns 158,889 shares of the biopharmaceutical company's stock worth $12,447,000 after buying an additional 130,108 shares during the period. Archer Investment Corp bought a new position in shares of Halozyme Therapeutics during the second quarter worth about $78,000. Finally, Livforsakringsbolaget Skandia Omsesidigt bought a new position in shares of Halozyme Therapeutics during the second quarter worth about $9,710,000. Institutional investors own 97.79% of the company's stock.

Insiders Place Their Bets

In other news, Director Mahesh Krishnan sold 7,304 shares of the business's stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the transaction, the director directly owned 14,462 shares in the company, valued at $1,084,650. The trade was a 33.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the company's stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the sale, the director directly owned 40,418 shares in the company, valued at approximately $4,154,970.40. The trade was a 3.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 42,478 shares of company stock valued at $3,767,304. 2.50% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Stock Up 1.1%

NASDAQ:HALO opened at $106.49 on Tuesday. Halozyme Therapeutics, Inc. has a twelve month low of $61.22 and a twelve month high of $109.66. The firm has a market capitalization of $12.09 billion, a price-to-earnings ratio of 31.79, a price-to-earnings-growth ratio of 0.42 and a beta of 0.85. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The stock's 50 day moving average price is $87.76 and its two-hundred day moving average price is $74.93.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The company had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. During the same quarter in the prior year, the firm posted $1.54 EPS. The firm's revenue for the quarter was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities research analysts expect that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Citigroup reaffirmed a "market outperform" rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. HC Wainwright lifted their price objective on shares of Halozyme Therapeutics from $95.00 to $115.00 and gave the company a "buy" rating in a report on Friday, August 7th. Wall Street Zen raised shares of Halozyme Therapeutics from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 8th. Morgan Stanley decreased their target price on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an "overweight" rating for the company in a research report on Tuesday, May 12th. Finally, Benchmark reiterated a "buy" rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Nine research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $91.20.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.